Clinical Trials Logo

Papillary Renal Cell Carcinoma clinical trials

View clinical trials related to Papillary Renal Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02489695 Completed - Clinical trials for Papillary Renal Cell Carcinoma

Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma

AXIPAP
Start date: October 2015
Phase: Phase 2
Study type: Interventional

Multicenter, single arm, phase II study using a A'Hern single-stage procedure in patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) in first-line treatment.

NCT ID: NCT00335556 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT00126503 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Start date: May 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of sorafenib tosylate and bevacizumab and to see how well they work in treating patients with advanced kidney cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth by targeting certain cells. Bevacizumab and sorafenib tosylate may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib tosylate together with bevacizumab may kill more tumor cells.